216 related articles for article (PubMed ID: 25501829)
1. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity.
Göbel C; Breitenbuecher F; Kalkavan H; Hähnel PS; Kasper S; Hoffarth S; Merches K; Schild H; Lang KS; Schuler M
Cell Death Dis; 2014 Dec; 5(12):e1568. PubMed ID: 25501829
[TBL] [Abstract][Full Text] [Related]
2. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
3. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
4. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
5. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
6. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
7. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
8. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
9. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
10. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
Tatum AM; Mylin LM; Bender SJ; Fischer MA; Vigliotti BA; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2008 Sep; 181(6):4406-17. PubMed ID: 18768900
[TBL] [Abstract][Full Text] [Related]
12. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
13. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
14. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
15. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
[TBL] [Abstract][Full Text] [Related]
16. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
17. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.
Teague RM; Sather BD; Sacks JA; Huang MZ; Dossett ML; Morimoto J; Tan X; Sutton SE; Cooke MP; Ohlén C; Greenberg PD
Nat Med; 2006 Mar; 12(3):335-41. PubMed ID: 16474399
[TBL] [Abstract][Full Text] [Related]
20. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
